Insmed to Present at the 2007 BIO Investor Forum on Wednesday, October 10, 2007

    RICHMOND, VA., October 3 /CNW/ - Insmed Inc. (Nasdaq:  INSM), a
biopharmaceutical company focused on the development and approval of drugs for
the treatment of metabolic diseases with unmet medical needs and the
development of a comprehensive portfolio of follow on biologics, today
announced that it will present at the 2007 BIO Investor Forum in San

    The conference, to be held at the Palace Hotel in San Francisco, will run
from Tuesday, October 9th through Thursday, October 11th. Steve Glover, the
President of Insmed Therapeutic Proteins will make the presentation on
Wednesday, October 10, 2007 at 6:15 p.m. Eastern Time (3:15 p.m. Pacific

    "We look forward to participating in the BIO Investor Forum where we will
provide an update on the progress of our dual-strategy growth plan based on
our proprietary protein platform and the development and manufacture of
follow-on biologics," said Mr. Glover.

    The Company will also hold one-on-one meetings with investment firm

    Individuals interested in listening to the live presentation via the
Internet may do so by visiting A replay will be available on
the Company's Web site for 30 days.

    About Insmed Incorporated

    Insmed, a development stage biopharmaceutical company with extensive
expertise in protein drug development, is pursuing a dual path strategy
involving entry into the follow on biologics arena (also known as biosimilars,
biogenerics and biologics) when the patents covering the innovator products
expire, and advancing its proprietary protein platform into niche markets with
unmet medical needs. For more information, please visit

    Forward Looking Statements

    This release contains forward-looking statements which are made pursuant
to provisions of Section 21E of the Securities Exchange Act of 1934. Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements. The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, we may
lack financial resources to complete development of product candidates, the
FDA may interpret the results of studies differently than us, competing
products may be more successful, demand for new pharmaceutical products may
decrease, the biopharmaceutical industry may experience negative market
trends, our entrance into the follow on biologics market may be unsuccessful,
our common stock could be delisted from the Nasdaq Global Market and other
risks and challenges detailed in our filings with the U.S. Securities and
Exchange Commission, including our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2007. Readers are cautioned not to place undue reliance
on any forward-looking statements which speak only as of the date of this
release. We undertake no obligation to publicly release the results of any
revisions to these forward-looking statements that may be made to reflect
events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.

For further information:

For further information: Investor Relations International Haris Tajyar,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890